Connect with us
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares...
Janssen increased its profit to €72.2 million last year. In total, Johnson&Johnson expects year-end revenue to be between $93 billion and $93.5 billion, while it expects...
In September, Grifols agreed to acquire the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG for $1.3 billion (€1.1 billion), which holds 90% of the...
The bond proceeds will be used to finance the $1.3 billion (€1.1 billion) purchase of the entire share capital of Tiancheng Pharmaceutical Holdings, which in turn...